Pharmaceutical composition for inhibiting the growth of cancers

A method of treating cancer in warm blooded mammals comprising administering a safe and effective amount of a pharmaceutical composition comprising a chemotherapeutic agent and N-phosphonoglycine of the formula:

• ##STR7## wherein X is selected from the group consisting of hydroxyl, alkoxy or chloroxyl up to 12 carbon atoms or lower alkenoxy;
• Y and Z each independently are selected from the group consisting of hydrogen and lower alkyl;
• and R is selected from the group consisting of hydrogen, formyl and acetyl;
• or pharmaceutically acceptable acid addition salts of said N-phosphonoglycine, which salts are selected from the group consisting of the Group I and II metals having an atomic number of up to 30, hydrochloride, acetate, salicylate, pyridine, ammonium, lower aliphatic hydrocarbon amine, lower alkanol amine and aniline.

A unit dosage composition comprising a safe and effective amount of a potentiator and N-phosphonoglycine of the formula:

• ##STR9## wherein X is selected from the group consisting of hydroxyl, alkoxy or chloroxyl up to 12 carbon atoms or lower alkenoxy;
• Y and Z each independently are selected from the group consisting of hydrogen and lower alkyl;
• and R is selected from the group consisting of hydrogen, formyl and acetyl;
• or pharmaceutically acceptable acid addition salts of said N-phosphonoglycine, which salts are selected from the group consisting of the Group I and II metals having an atomic number of up to 30, hydrochloride, acetate, salicylate, pyridine, ammonium, lower aliphatic hydrocarbon amine, lower alkanol amine and aniline and a pharmaceutically acceptable carrier.

A safe and effective treatment for viral infections comprising administering a safe and effective amount of a pharmaceutical composition comprising N-phosphonoglycine of the formula:

• ##STR10## wherein X is selected from the group consisting of hydroxyl, alkoxy or chloroxyl up to 12 carbon atoms or lower alkenoxy;
• Y and Z each independently are selected from the group consisting of hydrogen and lower alkyl;
• and R is selected from the group consisting of hydrogen, formyl and acetyl;
• or pharmaceutically acceptable acid addition salts of said N-phosphonoglycine, which salts are selected from the group consisting of the Group I and II metals having an atomic number of up to 30, hydrochloride, acetate, salicylate, pyridine, ammonium, lower aliphatic hydrocarbon amine, lower alkanol amine and aniline and a safe and effective amount of a potentiator.

A safe and effective treatment for viral infections comprising administering from about 15 mg/kg to about 150 mg/kg of a N-phosphonoglycine of the formula:

• ##STR11## wherein X is selected from the group consisting of hydroxyl, alkoxy or chloroxyl up to 12 carbon atoms or lower alkenoxy;
• Y and Z each independently are selected from the group consisting of hydrogen and lower alkyl;
• and R is selected from the group consisting of hydrogen, formyl and acetyl;
• or pharmaceutically acceptable acid addition salts of said N-phosphonoglycine, which salts are selected from the group consisting of the Group I and II metals having an atomic number of up to 30, hydrochloride, acetate, salicylate, pyridine, ammonium, lower aliphatic hydrocarbon amine, lower alkanol amine and aniline said N-phosphonoglycine and a safe and effective amount of a potentiator in a solid form.

A safe and effective treatment for herpes viral infections comprising administering a safe and effective amount of a pharmaceutical composition comprising a N-phosphonoglycine derivatives of the formula:

• ##STR12## wherein X is selected from the group consisting of hydroxyl, alkoxy or chloroxy up to 12 carbon atoms;
• lower alkenoxy;
• Y and Z each independently are selected from the group consisting of hydrogen and lower alkyl;
• and R is selected from the group consisting of hydrogen, formyl and acetyl and a safe and effective amount of a potentiator.